(250) Characteristics associated with RSV vaccination among adults aged 60 years and older in the United States between August 2023–February 2025

Background: : As of the 2023–2024 respiratory syncytial virus (RSV) season in the United States (US), RSV vaccination was available for adults aged ≥60 years. The Centers for Disease Control and Prevention recommended RSV vaccination with shared clinical decision-making in June 2023 for this population and updated the recommendation in June 2024 to all adults aged ≥75 years and those aged 60–74 years at increased risk of severe RSV disease. Uptake of RSV vaccination remains limited in the US.

Objective: : To understand characteristics associated with the likelihood of RSV vaccination among US adults aged ≥60 years.

Methods: : This retrospective study used IQVIA’s open-source pharmacy (LRx) and medical (Dx) claims data, and consumer attribute (Cx) data from August 1, 2023–February 28, 2025. The analysis included adults aged ≥60 years with ≥1 claim (LRx or Dx) in 2023; linkage between LRx, Dx, and Cx; and evidence of ≥1 year of data availability before August 2023. For patients who did not receive an RSV vaccine in 2023, an additional claim was required from January 1, 2024–February 28, 2025 as evidence of data availability. Multivariable logistic regression identified characteristics associated with likelihood of vaccination during the study period, reporting adjusted odds ratios (aOR). Independent variables included demographic, clinical, and social determinant of health measures.

Results: : Data from 16,799,689 adults aged ≥60 years were analyzed with RSV vaccination uptake of 23.27%. Receipt of any other vaccination was the strongest observed association with an aOR of 23.55 (95% confidence interval [CI] 23.42–23.69). Increasing age group from 60–64 (reference) to 75–79 years (aOR 1.53 [95% CI 1.52–1.54]) was associated with increasing likelihood of RSV vaccination. Aged ≥80 years was the only exception to this pattern (aOR 1.37 [95% CI 1.36–1.38]). Medicare vs commercial insurance was associated with higher odds of vaccination (aOR 2.98 [95% CI 2.97–2.99]). Compared to those without risk factors associated with severe RSV disease, certain conditions were associated with increased likelihood of RSV vaccination, including immunosuppressing conditions or chronic pulmonary disease. Higher income and education were associated with higher odds of RSV vaccination. Lower odds of RSV vaccination were observed for Hispanic adults and non-Hispanic Black adults compared to non-Hispanic White adults.

Conclusions: : Significant variability in the likelihood of RSV vaccination among adults aged ≥60 years was observed. These findings may help inform future efforts to support appropriate vaccination of eligible adults.

Sponsorship:: GSK VEO-001086